First-Line Treatment of Unresectable or Metastatic Cutaneous Melanoma with BRAF V600 Mutation
Patients with unresectable and/or metastatic cutaneous melanoma whose tumour carries a BRAF V600 mutation represent a distinct subgroup with dedicated first-line treatment pathways.
Clinical Scenario
Unresectable and/or metastatic cutaneous melanoma with confirmed BRAF mutation (V600). Mutation status in this setting is clinically significant, as it determines eligibility for specific treatment categories.
Treatment Approach — partial overview
First-line therapy for this scenario includes both immunotherapy combination approaches and BRAF/MEK-targeted therapy options, with immunotherapy combinations representing the preferred first choice over targeted agents — the complete regimen options and selection criteria are available in the full protocol.
References
- For patients with BRAF mutant (V600) unresectable and/or metastatic cutaneous melanoma, one of the following treatment options should be offered as first-line therapy: nivolumab plus ipilimumab followed by nivolumab OR nivolumab plus relatlimab OR nivolumab OR pembrolizumab OR dabrafenib plus trametinib OR encorafenib plus binimetinib OR vemurafenib plus cobimetinib.
- Combination therapy with nivolumab plus ipilimumab is preferred as first-line therapy over BRAF/MEK inhibitor combination therapy.
DOI: 10.1200/JCO.23.01136
View source ↗